Breast cancer Trials in Changhua, Taiwan
Conditions / Breast cancer / Changhua, Taiwan
Breast cancer has been the subject of sustained clinical investigation across multiple research sites.
24 total trials for this combination
Showing top 10 of 24 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06492616 | A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence | RECRUITING | — |
| NCT06016738 | OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer | RECRUITING | PHASE3 |
| NCT02032823 | Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT06112379 | A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT02513394 | PALbociclib CoLlaborative Adjuvant Study | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT01358877 | A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer | COMPLETED | PHASE3 |
| NCT03155997 | Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer | ACTIVE_NOT_RECRUITING | — |
| NCT00528567 | BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer | COMPLETED | PHASE3 |
| NCT06533059 | A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors | RECRUITING | PHASE1 |
| NCT00625898 | BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab | TERMINATED | PHASE3 |